Minerva Neurosciences, Inc (NERV) Short Interest Update

Minerva Neurosciences, Inc (NASDAQ:NERV) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,179,041 shares, a decline of 35.4% from the January 12th total of 1,825,699 shares. Based on an average trading volume of 273,059 shares, the days-to-cover ratio is currently 4.3 days. Approximately 3.6% of the shares of the stock are sold short.

Minerva Neurosciences (NERV) opened at $5.55 on Monday. The firm has a market cap of $214.79, a PE ratio of -5.00 and a beta of 1.49. Minerva Neurosciences has a fifty-two week low of $4.80 and a fifty-two week high of $11.15.

A number of research firms recently weighed in on NERV. ValuEngine lowered shares of Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. BidaskClub upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. Minerva Neurosciences has an average rating of “Hold” and an average target price of $13.94.

In related news, CFO Geoff Race sold 5,829 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $5.79, for a total transaction of $33,749.91. Following the transaction, the chief financial officer now directly owns 197,698 shares in the company, valued at $1,144,671.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 12,590 shares of company stock worth $73,073 over the last 90 days. 21.60% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the business. Nationwide Fund Advisors boosted its holdings in Minerva Neurosciences by 861.1% in the 3rd quarter. Nationwide Fund Advisors now owns 124,990 shares of the biopharmaceutical company’s stock valued at $950,000 after purchasing an additional 111,985 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Minerva Neurosciences by 14.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,074,239 shares of the biopharmaceutical company’s stock valued at $9,507,000 after purchasing an additional 134,942 shares during the last quarter. Northern Trust Corp boosted its holdings in Minerva Neurosciences by 27.9% in the 2nd quarter. Northern Trust Corp now owns 298,507 shares of the biopharmaceutical company’s stock valued at $2,641,000 after purchasing an additional 65,056 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Minerva Neurosciences by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 90,929 shares of the biopharmaceutical company’s stock valued at $805,000 after purchasing an additional 10,728 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its holdings in Minerva Neurosciences by 69.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 84,245 shares of the biopharmaceutical company’s stock valued at $746,000 after purchasing an additional 34,572 shares during the last quarter. Institutional investors own 73.65% of the company’s stock.

WARNING: “Minerva Neurosciences, Inc (NERV) Short Interest Update” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/12/minerva-neurosciences-inc-nerv-short-interest-update.html.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply